Treatment-related mortality in children with acute myeloid leukaemia in Central America: Incidence, timing and predictors

被引:36
|
作者
Gupta, Sumit [1 ,2 ]
Bonilla, Miguel [3 ]
Valverde, Patricia [4 ]
Fu, Ligia [5 ]
Howard, Scott C. [6 ]
Ribeiro, Raul C. [6 ]
Sung, Lillian [1 ,2 ]
机构
[1] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada
[2] Hosp Sick Children, Program Child Hlth Evaluat Sci, Toronto, ON M5G 1X8, Canada
[3] Hosp Nacl Ninos Benjamin Bloom, San Salvador, El Salvador
[4] Unidad Nacl Oncol Pediat, Guatemala City, Guatemala
[5] Hosp Escuela Tegucigalpa, Tegucigalpa, Honduras
[6] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
基金
加拿大健康研究院;
关键词
Acute myeloid leukaemia; Central America; Child; Developing countries; Treatment related death; TREATMENT-RELATED DEATHS; NUTRITIONAL-STATUS; INDUCTION THERAPY; ONCOLOGY-GROUP; EL SALVADOR; CHILDHOOD; CANCER; TRIAL; AML; EXPERIENCE;
D O I
10.1016/j.ejca.2011.10.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cure rates in paediatric acute myeloid leukaemia in low-income countries lag behind those in high-income countries, in part secondary to higher rates of treatment-related mortality. Patterns of treatment-related mortality are likely to differ between low and high-income centres. Understanding low-income setting patterns is necessary before effective interventions aimed at decreasing treatment-related mortality can be designed. Our aim was to describe the incidence, timing and predictors of treatment-related mortality among Central American children with acute myeloid leukaemia. Patients and methods: We evaluated patients younger than 21 years diagnosed with acute myeloid leukaemia from 2000 to 2008 in El Salvador, Honduras or Guatemala. Biologic, socioeconomic and nutritional variables collected prospectively were examined as potential predictors of treatment-related mortality. Results: Among 279 patients, treatment-related mortality occurred in 65 (23%). Of 65 deaths, 51 (78.5%) occurred before or during induction, resulting in an early death rate of 18.3%. The most common causes of treatment-related mortality were infection (29/65; 45%) and haemorrhage (13/65; 20%). Infection accounted for 33% of treatment-related mortality before remission induction therapy versus 40% during induction and 77% after induction (P = 0.03). Rates of treatment-related mortality did not vary between time periods 1 and 2 (24.8% versus 21.4%; P = 0.32). Only lower initial platelet count predicted early death (odds ratio per 10 x 10(9)/L = 0.88, 95% Confidence Interval (CI) 0.79-0.97; P < 0.001). Conclusions: Treatment-related mortality remains a significant cause of treatment failure. Supportive care interventions are needed. Children presenting with low initial platelet counts were at highest risk of induction death, suggesting that transfusion practices should be evaluated. (C) 2011 Elsevier Ltd. All rights reserved.
引用
下载
收藏
页码:1363 / 1369
页数:7
相关论文
共 50 条
  • [41] IV busulfan and fludarabine as conditioning regimen in acute myeloid leukaemia: low treatment-related mortality and acceptable antileukaemic activity. Analysis of a single-centre experience to date
    Rodriguez Macias, G.
    Munoz Martinez, C.
    Gayoso, J.
    Balsalobre, P.
    Buno, I.
    Serrano, D.
    Kwon, M.
    Encinas, C.
    Font, P.
    Noriega, V.
    Gomez-Pineda, A.
    Anguita, J.
    Diez-Martin, J. L.
    BONE MARROW TRANSPLANTATION, 2010, 45 : S416 - S417
  • [42] Treatment-related Myelodysplastic Syndrome in a Child With Acute Myeloid Leukemia and TPMT Heterozygosity
    Stensman, Lars M.
    Kjeldsen, Eigil
    Nersting, Jacob
    Schmiegelow, Kjeld
    Hasle, Henrik
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (04) : E242 - E244
  • [43] THE INCIDENCE AND OUTCOME OF SOMATIC WT1 MUTATIONS IN CHILDREN WITH ACUTE MYELOID LEUKAEMIA
    Bandopadhayay, Pratiti
    Titgemeyer, Carola
    Siswara, Priscillia
    Dagar, Vinod
    Barton, Rebecca
    Downie, Peter
    MeChinaud, Francoise
    Ekert, Paul
    Algar, Elizabeth
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 773 - 773
  • [44] Outcome of Children Treated for Relapsed Acute Myeloid Leukemia in Central America
    Marjerrison, Stacey
    Antillon, Federico
    Bonilla, Miguel
    Fu, Ligia
    Martinez, Roxana
    Valverde, Patricia
    Vasquez, Roberto
    Howard, Scott C.
    Ribeiro, Raul C.
    Sung, Lillian
    PEDIATRIC BLOOD & CANCER, 2014, 61 (07) : 1222 - 1226
  • [45] Risk Factors for Treatment Related Mortality in Childhood Acute Lymphoblastic Leukaemia
    Lund, Bendik
    Asberg, Ann
    Heyman, Mats
    Kanerva, Jukka
    Harila-Saari, Arja
    Hasle, Henrik
    Soderhall, Stefan
    Jonsson, Olafur Gisli
    Lydersen, Stian
    Schmiegelow, Kjeld
    PEDIATRIC BLOOD & CANCER, 2011, 56 (04) : 551 - 559
  • [46] Decreased Relapsed Rate and Treatment-Related Mortality Contribute to Improved Outcomes for Pediatric Acute Myeloid Leukemia in Successive Clinical Trials
    Alexander, Thomas B.
    Wang, Lei
    Inaba, Hiroto
    Triplett, Brandon M.
    Pounds, Stanley
    Ribeiro, Raul C.
    Pui, Ching-Hon
    Rubnitz, Jeffrey E.
    CANCER, 2017, 123 (19) : 3791 - 3798
  • [47] Incidence, Predictors And Mortality Related To Post-stroke Antidepressant Treatment
    Mortensen, Janne K.
    Larsson, Heidi
    Johnsen, Soren P.
    Andersen, Grethe
    STROKE, 2015, 46
  • [48] Treatment-related death in childhood acute lymphoblastic leukaemia in the Nordic countries:: 1992-2001
    Christensen, MS
    Heyman, M
    Möttönen, M
    Zeller, B
    Jonmundsson, G
    Hasle, H
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 131 (01) : 50 - 58
  • [49] ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH TREATMENT-RELATED ACUTE MYELOID LEUKEMIA
    Lojko, A.
    Czyz, A.
    Matuszak, M.
    Gil, L.
    Nowicki, A.
    Dytfeld, D.
    Komarnicki, M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S118 - S118
  • [50] Treatment-related acute myeloid leukemia in a chronic lymphocytic leukemia patient: role of fludarabine?
    Giri, Smith
    Bhatt, Vijaya Raj
    Khanal, Sumesh
    Ganti, Apar Kishor
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2015, 6 (02) : 88 - 92